TaiMed Announces Significant Progress in Clinical Trials for New HIV Treatment
- Written by PR Newswire
Company champions long-acting HIV therapy with new biologic drug TMB-365/380 combination; after favorable results of Phase 1b/2a, company plans to accelerate Phase 2 clincial study to expedite path to market
TAIPEI, Oct. 16, 2023 /PRNewswire/ -- TaiMed Biologics, an innovation-driven biotech company dedicated to serving unmet healthcare needs,...
Read more: TaiMed Announces Significant Progress in Clinical Trials for New HIV Treatment














